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The Impact of Sex and Gender on Innovation and Health Technology1
Dima Elissa, Dr. Neelum Aggarwal, Natalie Ficek, Kyle Mitchell, Sophia Pribus,
Throughout history, there has been an unsettling partiality for men in the healthcare
industry. A leading example highlighting this problem is heart disease and the long history of its
treatment plans directed towards men. In 1982, a study on cholesterol and its impact on
cardiovascular disease involved 12,866 men and no women.2 In addition to clinical trials, the
focus on men was also evident in the area of medical education, where a diverse group of
diseases, progression, symptomatology and treatments were described with little to no comment
as to whether sex differences were apparent.3 To this day, the implications of heart disease as
being a man’s disease are significant, since women continue to be under recognized by health
professionals when they have symptoms of heart disease. Since women are less likely to be
tested for and diagnosed with heart disease due to uncommon symptoms, the available data and
clinical course data continue to be two areas that are understudied. In addition to the diagnostic
problem, the available treatment options continue to be tailored to men and thus are less suitable
for women.
In 1993, the National Institutes of Health (NIH) passed the NIH Revitalization Act,
which ensured the inclusion of women and minorities in clinical research.4 Clinical trials must
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include women and minorities unless there is a clear and compelling rationale and justification
for exclusion.5 For example, excluding women from prostate studies would be an adequate
rationale, but cost is not an acceptable reason for exclusion. In addition to including women and
minorities, researchers must design and carry out trials in a manner that sufficiently provides
valid analysis based upon the proposed research plan. The plan and/or proposal must outline the
composition of the study population and describe why that particular population was chosen.
Why is Heart Disease a “Man’s Disease”?
In the 1700s, the heart was linked to emotion, particularly anger.6 In the late nineteenth
century, William Osler, a physician, challenged this idea by arguing that heart disease was
caused by stress.7 He identified a typical heart disease patient as a “keen and ambitious man, the
indicator of whose engine is always ‘full speed ahead.”8 By the 1950s, even though heart disease
had been linked to diet, exercise, and other physical factors, it was still considered only a man’s
disease and lifestyle recommendations if made, were directed to at risk men.9
Fast forward to a 1995 study on aspirin and heart disease.10 Even though the NIH
Revitalization Act was passed in 1993, which stated that women and minorities must be
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represented in clinical trials,11 this study recruited over 22,000 persons, and only involved men.
Medical illustrations, an important area in medical education and training, also had a
noticeable male focus.12 Harlan Krumholz, the editor of the New England Journal of Medicine,
recalled the iconic drawings of Frank Netter, one of the most famous medical illustrators of the
twentieth century-Netter’s illustrations, and stated there were very few illustrations, that
depicted a woman with heart disease.”13
Sex Differences
A. Structural Differences of the Heart
While there are no statistically significant sex-related differences in the heart during
puberty, there are differences in male and female hearts after puberty. Notably, heart mass is
fifteen to thirty percent bigger in males than in females14 and thought to be due to myocytes
undergoing a greater degree of hypertrophy in males compared to females.15 It is unclear
whether this solely occurs due to the role of sex hormones, particularly estrogen, which provides
cardio-protection16 or whether genes located on the X chromosomes are expressed at higher
levels in females than in males.17 In addition, males express genes on the Y chromosome, which
are clearly not present in females.18 Apart from the genetic contributions, other likely proteins
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that may contribute to sex differences in cardiac structure and functioning, include calmodulindependent protein kinase, Akt, glycogen synthase kinase 3B, and myocyte enhancer factor 2
signaling proteins.19
Another sex-related difference in the structure of the heart is the anatomic location of
major vessels. Even though vessels are composed of the same cell types for both men and
women, their functions vary. According to several studies, left ventricular systolic function
influenced by the anatomic geometry of the left ventricle and left ventricle geometry differs
between men and women.20 The dual-chambered pump is smaller in women than in men, which
translates into a smaller stroke volume and thus, a lower cardiac output.21 In addition, the heart
rate (also known as the rate of pumping) is greater in females than in males, except in utero.22
One study on atherosclerosis that evaluated age-related left ventricle (LV) remodeling
found that as patients age, the LV responds differently in its mass and volume between men and
women.23 According to the results from the The Multi-Ethnic Study of Atherosclerosis (MESA)
study, LV mass was found to be increased in men (8.0 g) and decreased in women (-1.6 g) and
the LV end-diastolic volume decreased for both men (-9.8) and women (-13.3) per decade.24
There are also differences in the electrical activity of cardiac myocytes.25 Typically,
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women’s electrocardiography (ECG) tests show a longer QT interval after puberty compared to
men.26
Even the composition of the blood circulating in the body vary between men and women.
Females have a lower number of circulating red blood cells per unit volume of plasma, often
noted as a lower hematocrit.27 The amount of high-density lipoprotein (HDL) is higher and
triglycerides are lower in females, pre-menopause, than in males and is associated with a lower
incidence of cardiovascular disease.28 However, after menopause, the lipoprotein profile of
females becomes more atherogenic and is correlated with the higher incidence of heart disease in
that population.29 These physiological changes between the sexes is important for clinical
screening protocols, treatment and clinical trial design and data analyses.
Sex-related differences also appear during cardiovascular stress. Generally, men respond
to cardiovascular stress by increasing vascular resistance, which manifests as an increase in
blood pressure.30 On the other hand, women respond to stress by increasing their heart rate,
which increases cardiac output.31 In addition, blood pressure control through the baroflex system
differs between men and women.32 Men have higher plasma norepinephrine levels than
women33 and women have reduced sympathetic activity and parasympathetic activity relative to
men.34 Consequently, women are more vulnerable to orthostatic hypotension and fainting than
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men due to their body position and fluid shifts.35 Even though the mechanisms underlying sex
differences are not understood, estrogen and testosterone play a significant role, with testosterone
in the development of and estrogen in the protection against high blood pressure.36
B. Sex Differences in the Regulation of Blood Pressure
According to Reckelhoff, “[m]en are at a greater risk for cardiovascular and renal disease
than are age-matched, premenopausal women.”37 According to recent studies in which 24-hour
ambulatory blood pressure monitoring techniques were used, men had higher blood pressure than
women by about 6–10 mmHg.38 However, after menopause, women had higher blood pressure
levels than men.39 One possible explanation for this finding is that pre-menopause, estrogen is
responsible for stimulating nitric oxide production, thereby activating a vasodilator pathway, and
regulating blood pressures. At or after menopause, the loss of estrogen can result in the
dysregulation of this pathway, which subsequently can increase blood pressures.40
C. Sex Hormones
Sex hormones are also thought to cause the variation in cardiovascular effects between
men and women. While premenopausal women have a low incidence of cardiovascular disease
compared to men, the incidence level rises to the same or even more for women postmenopause.41 Both androgens and estrogens influence a multitude of vascular biological
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processes and their cardiovascular effects are multifaceted.”42 Consequently, high androgen
levels and low estrogens plasma concentrations have been respectively related to the increased
impact of CVD in men and in postmenopausal women.43
In addition, risk factors have varying degrees of weight between men and women,
especially in the presence of an ovarian deficiency state, when the drop in sex hormones
negatively affects several conditions such as hyperinsulinaemia, obesity, high cholesterol and
blood pressure.44 After menopause, women develop a pro-atherogenic lipid profile because of
impaired estrogen production”45 increased tendency for a sedentary lifestyle and both body fat
distribution and glucose metabolism increase the risk of CVD.
In terms of glucose metabolism, while the risk of CVD in both men and women is
significantly increased in diabetes cases and with an altered glucose metabolism, the probability
of future cardiovascular events is greater in women with diabetes than in men, especially when
the disease is associated with increased blood pressure.46 Diabetic women have lower estrogen
levels than non-diabetic women, and it has been shown to cause a progressive decline in glucosestimulated insulin secretion, and to increase insulin resistance by reducing insulin sensitivity. 47
Some earlier studies showed that hormone replacement therapy (HRT) was beneficial for
primary cardiovascular prevention.48 Conversely, a post-analysis of the results of the
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Framingham Study clearly showed that HRT is protective in younger women, but can be harmful
to those starting treatment late, and especially after the age of sixty.49
Estrogen may be beneficial for both genders, but the effect of androgens differs between
men and women.50 For women, the effect of testosterone depends on background estrogen
levels, whereas for men, the effect of testosterone depends on its aromatization into estradiol.51
While androgen replacement in women does not increase cardiovascular risk, replacement
therapy in men may be beneficial, but long-term interventional studies with physiological
androgen doses are lacking and therefore warranted.52
NIH/FDA Guidelines & Funding Changes
The NIH Revitalization Act of 1993 ensured the inclusion of women and minorities in
clinical research, which also includes clinical trials.53 In addition, the statute provides that when
women and minorities are included as subjects, the trial must be designed and carried out in a
manner sufficient to provide for valid data analysis.54 An issue arises with this provision because
clinical researchers do not conduct internal analyses stratifying their results between
men/women, female/male, race routinely or report these data results in the final publication.
In May 2014, the NIH took a more focused approach to identify steps to address sex
differences in preclinical research.55 As part of new policies, the NIH “require[d] applicants to
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report their cell and animal inclusion plans as part of preclinical experimental design”56 and note
this in their grant applications. In theory this policy would promote “a balanced approach to
addressing male and female differences in cells and animals.”57
In June 2015, the NIH took the initiative to include sex as a variable in research by
announcing some changes to the “instructions for scientists applying for NIH funding” and by
“revising criteria for the reviewers who judge the funding applications.”58 The NIH highlighted
“that sex as a biological variable will be factored into research designs, analyses, and reporting in
vertebrate animal and human studies.”59 Thus, the NIH made sex a fundamental biological
variable that must be considered in research to ensure both men and women receive full benefits
from medical research and also guide further research. Further, “[s]cientists proposing to study
only one sex will be required to provide strong justification from the scientific literature,
preliminary data, or other relevant considerations.”60
In 2016, a new law mandated that every funding application submitted to the NIH after
January 1, 2016, would need to describe the research or study proposed in the context of sex and
gender.61 The reasoning behind this new law was to ensure that research not only gave thought
about this criteria, but that preclinical research studies include women. It is problematic to only
have preclinical studies on one sex or gender, especially with studies that are intended to inform
understanding of diseases and conditions affecting both sexes. Failure to account for sex as a
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biological variable may undermine the rigor, transparency, and generalizability of research
findings to the general population.”62
The Food and Drug Administration (FDA) Office of Women’s Health (OWH) also has its
mission aligned to “[a]dvocate for the inclusion of women in clinical trials”63 and therefore, all
clinical trials must consider sex and gender in order to obtain FDA approval. As such, the FDA
outlined an action plan in Section 907 of the FDA Safety and Innovation Act (FDASIA), which
had the following three overarching priorities to help direct their activities:
1. Quality: to improve the completeness and quality of demographic subgroup data;
2. Participation: to identify barriers to subgroup enrollment in clinical trials and employ
strategies to encounter greater participation;
3. Transparency: to improve the public availability of demographic subgroup data.”64
In addition to the above priorities, enhancing innovation in the areas of drug and medical devices
have also been part of the mission of the FDA.65
A. Impact & Implications
Even with new innovations such as drugs and devices, there still exists an unsettling
partiality for men in healthcare.
a. New Innovations

Including Women and Minorities in Clinical Research, U.S. DEP’T OF HEALTH & HUMAN
SERV. – NAT’L INST. OF HEALTH OFFICE OF RESEARCH ON WOMEN’S HEALTH,
https://orwh.od.nih.gov/clinical/women-and-minorities/.
63
Protecting and Advancing Women’s Health, FDA OFFICE OF WOMEN’S HEALTH at i,
https://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm13537
6.pdf.
64
FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials, FDA,
https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstothe
FDCAct/FDASIA/ucm389100.htm.
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i. Drugs
While the FDA is engaged in both data collection and policy development, it is still
important to include women in all stages of NIH-sponsored trials.66 These trials can help clarify
the understanding of diseases, treatment regimens, and care delivery.67 Women make up one of
the most frequent subgroups of patients for a variety of medical conditions.68 A primary reason
for the past exclusion of women in clinical trials was the concern of exposing a future fetus to
experimental drugs.69 While still subject to concern today, this conception was challenged in the
1990s, when HIV-infected women found themselves ineligible to participate in trials of new
antiviral therapies.70 This issue was exacerbated by the fact that there were very few alternative
treatments available.71 The FDA has addressed this issue by formulating steps to facilitate the
inclusion of premenopausal women into clinical trials.72 To ensure safety, these steps are subject
to certain exceptions. In addition to the challenge of treating women before they have reached
menopause, there lies the even more daunting challenge of treating women who are already
pregnant. There remains widespread caution in treating pregnant women with investigational

U.S. Senate Comm. – Health, Educ., Labor & Pensions, Democratic Senate and House
Leaders Request GAO Study on Inclusion of Women in NIH-Supported Clinical Trials (Apr. 30,
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67
Id.
68
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(Oct. 9, 2009).
69
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70
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71
Id. See also Haley Gorenberg & Amanda White, Off the Pedestal and into the Arena: Toward
Including Women in Experimental Protocols, 19(1) REV. LAW SOC. CHANGE 205-46 (1991-92).
72
Berlin, supra note 68. See also R.B. Merkatz & S.W. Junod, Historical background of changes
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MED. COL. 703, 703-07 (Sept. 1994).
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drugs to protect the developing fetus.73 This leaves pregnant women with very little information
when making a decision on treatment because there is no past data of the potential effects of
specific experimental treatments on pregnant women.
One exception to this are the experimental trials with the H1N1 flu vaccine.74 These
followed the recommendation of the Center for Disease Control and Prevention and the American
College of Obstetricians and Gynecologists based on a 2009 study in the Lancet Medical Journal,
which found that pregnant women were four times more likely to be hospitalized from H1N1 than
the general population.75 Because pregnant women are considered to be in the high-risk group for
this infection, the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS)
conducted a national survey of 1,032 pregnant women who either were or were not vaccinated
between 2009 and 2012.76 The study concluded that “pregnant women who were vaccinated were
no more likely to have a miscarriage, a baby born with a birth defect or a baby born smaller than
normal, compared with a women who did not get a vaccination.”77
The issue of the under inclusion of women in clinical studies of experimental drugs was
addressed in 2001 by the Government Accountability Office (GAO). The GAO reported that
although women made up over fifty percent of the study participants for new drug applications,
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only twenty-two percent of early stage clinical trials were made up of women.78 This is cause for
concern, as phase 1 trials are structured around the assessment of safety and help set initial dosing
levels.79 This same problem resurfaced in the 2006 and 2007 reviews of clinical trials that were
done to support the approval of new drugs.80 The review revealed that women were still
underrepresented in phase 1 trials, compromising approximately only one-third of participants.81
ii. Devices
It has been over twenty years since the enactment of the NIH Revitalization Act, and there
still remains a reluctance to conduct sex-specific analyses and report sex-based differences in
medical device clinical trials.82 As a result, there remains a dearth of information in regards to
potential sex differences in dosing, safety, and effectiveness, some of which could have been
detected in earlier stages of research had females been included.83 In December 2011, the FDA
issued a draft guidance entitled Evaluation of Sex of Differences in Medical Device Clinical
Studies, which advocated for an adequate inclusion of women in trials and the reporting of the
analysis of sex-based differences.84 In its guidance, the FDA stressed the importance of such

U.S. Senate Comm. – Health, Educ., Labor & Pensions, supra note 66; see also General
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representation in medical device clinical trials.85 A study of the progression in sex-specific
analysis and reporting over time was conducted by utilizing the website ClinicalTrials.gov.86 The
website was chosen because it is one of the fundamental resource for seeking information about
clinical trials and their study results.87 The results of the search yielded eighty-seven studies with
a majority (ninety-seven percent) reporting the sex of their participants.88 While the average
representation of women in device clinical trials was fifty percent, the average rate of female
participation was categorized by target disease category and was thirty-four percent lower in
studies on cardiovascular disease than in all other categories.89

A similar study involving

cardiovascular devices that obtained premarket approval by the FDA was conducted from 2000 to
2007. The results concluded that women made up less than one-third of the subject population.90
It is important to note that although the aforementioned studies demonstrate that women are
underrepresented as participants in clinical device studies, many of these reviews are not required
to report sex-specific analysis.91 This reveals not only a persistent pattern of women being
underrepresented in cardiovascular device trials but also shows a lack of enforcement by the FDA
in regulating its own reporting directives.92
A similar study was conducted on the difference between sexes in randomized trials of
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implantable cardioverter-defibrillator (ICD) therapy in high-risk patients.93 The AVID trial was a
large U.S. study that enrolled patients who had survived cardiac arrest due to ventricular
fibrillation, syncopal VT, or symptomatic VT94 and yet, in this important study, only twenty-one
percent of the recruited patients were women.95
B. NIH Funding Rules/Considerations
The NIH Revitalization Act also has implications on the potential for investments needed
to conduct certain clinical studies. In 2014, the NIH invested $10.1 million to assist eighty-two
grantees in conducting research exploring the effects of sex in preclinical and clinical studies.96
This program was launched in the fiscal year of 2013 under leadership from the Office of Research
on Women’s Health.97 The grantees’ projects spanned a wide range of scientific topics including,
but not limited to (1) basic immunization, (2) cardiovascular physiology, (3) neural circuitry, and
(4) behavioral health.98 The investment was meant to encourage researchers to study both sexes
as a fundamental variable in research.99 Including both sexes in clinical studies is important as an
overreliance on male subjects in preclinical research can obscure key findings related to sex that
could help guide later studies.100 Discussing the importance of the program, Janine Austin
Clayton, the NIH Associate Director for Women’s Health Research, remarked: “[t]his funding
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strategy demonstrates our commitment to moving the needle toward better health for all
Americans, while helping grow our knowledge base for both sexes and building research
infrastructure to aid future studies.”101 She further stated, “scientists receiving these awards have
approached their research questions with fresh thinking, and are looking for innovation and
discovery through a new lens.”102
C. Evidence-Based Examples of Gender and Sex in Healthcare Treatments
a. Cardiology
There are many known differences between men and women in heart disease, but the
reason is still unknown, which is a problem. The 1980s illustrated the complete lack of inclusion
of women in mainstream medical studies.103 Two of the major cardiovascular studies include (1)
the Physicians’ Health Study on the effects of aspirin on cardiovascular disease, in which 22,071
men and zero women physicians were enrolled,104 and (2) the Multiple Risk Factor Intervention
Trial (MRFIT)—a randomized trial evaluating correlations among blood pressure, smoking,
cholesterol, and coronary heart disease—in which 12,866 men and zero women were
participants.105
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A more recent study involved a federally funded analysis of MRI scans of the hearts of
approximately 3,000 male and female adults.106 The MRIs showed a significant difference in the
way male and female hearts age over time.107 Specifically, as men age, the heart muscle that
surrounds the main heart chamber grows bigger and thicker.108 In contrast, as women age, the
same chamber either retains its size or gets smaller.109 Although these results fail to explain the
cause of the difference between the sexes, they may still illustrate the varying forms of heart failure
in men and women, which would require sex-specific treatments.110 Doctor John Eng, a lead
investigator of the study, concluded that a “[t]hicker heart muscle and smaller heart chamber
volume both portend heightened risk of age-related heart failure, but the gender variations we
observed mean men and women may develop the disease for different reasons.”111 Because heart
failure is currently treated by the prescription of medication designed to reduce the thickness of
the heart muscle over time and because women’s hearts may shrink with age, this treatment method
is less beneficial to women patients.112
b. Neuro (degenerative)
Alzheimer’s

disease

(AD)

is

a

progressive

neurodegenerative

disorder

that

disproportionately affects women in both prevalence and severity.113 Symptoms include memory
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loss, cognitive deficits, and behavioral changes.114 Although AD was identified over one-hundred
years ago, there is still little known about what triggers it.115 Because of this, the current available
treatments are unable to slow or reverse the damage it causes.116 The chemical nature of AD is
characterized by the accumulation of two proteins in the brain: amyloid and tau.117 Amyloid
precursor proteins are divided into smaller amyloid fragments through an unknown process.118
These fragments accumulate and cause plaque deposits to collect in the extracellular spaces, thus
disrupting nerve-to-nerve communications and causing fibers to swell as well as other
morphologic changes.119 Tau is a protein that typically binds and stabilizes components of the
neurons of the brain.120 In AD, tau accumulation forms neurofibrillary tangles that can disrupt
important signaling.121 These two processes cause selective neuronal cell death, contributing to
the disease’s progression.122
AD’s disproportionate effect on women can stem from the difference in biological
mechanisms between sexes, including brain anatomy, age-related declines in brain volume, or
brain glucose metabolism.123 In the United States, approximately 3.4 million women over the age
of sixty-five are affected by AD compared to 1.8 million men.124 It is speculated that in addition
to the above-mentioned biological difference, the longevity of women’s lives may play a role.125
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One study compared global cognitive function to measures of plaque and tangle pathology derived
from brain autopsies.126 AD pathology was much more likely to be associated with dementia in
women than men. Additionally, it was found that women had nearly three times the odds of being
diagnosed with AD.127 AD pathogeneses may also be affected by a change in metabolisms caused
by sex hormones.128 Estrogen is known to serve as a brain protectant, and its loss of production
during menopause may be responsible for deficits in brain metabolism, leading to a higher risk of
AD.129 With the relationship between gender differences and the onset of AD still ill-defined, it
is important to gain more knowledge on the interplay between genetic, hormonal, and
environmental factors.130
c. Ortho
Women have a higher rate of osteoporosis-related hip fractures than men.131 There are
many quantitative differences between how men and women develop common musculoskeletal
disorders. Anterior cruciate ligament injuries occur two to eight times more frequently in women
than men.132 Women are five to eight times more likely to suffer an ACL injury than men in highintensity sports that require sudden changes in motion.133 Women are twice as likely to sprain
their ankles than men and are generally more susceptible than men to develop osteoarthritis of the
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knee.134 Women may be more vulnerable to ligament tears because of the reproductive hormones
that affect joint laxity.135 When looking at orthopedic ailments in relation to an increase in age,
women are more likely to develop osteoporosis than men.136 This leads to a higher risk of hip,
wrist, and vertebral spine fractures.137
d. Autoimmune
An autoimmune disease is one in which the body produces autoantibodies that attack
normal healthy cells by mistake.138 While autoimmune diseases affect both men and women, the
majority (approximately seventy-five percent) are women.139 Specifically, autoimmune diseases
are one of the leading causes of death and disability in women sixty-five and younger.140 While
there is not yet an exact reason why women are more susceptible to autoimmune diseases than
men, there are a few probable theories.141 First, women may be at a higher risk of autoimmune
diseases because of their more sophisticated immune systems.142 As there is a correlation between
inflammation and autoimmune disease, the fact that women’s inflammatory responses are stronger
than men’s leads to a potential for more frequent disease. Second, women’s hormones may play
a role in the potential for disease and autoimmune flare ups often associated with hormonal
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fluctuations.143 Hormonal fluctuations can occur during pregnancy, the menstrual cycle, or when
using certain contraceptives.144 In addition to these theories, there are a multitude of autoimmune
diseases that significantly affect women over men. These include Hashimoto’s thyroiditis, Graves’
disease, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus (lupus), and
rheumatoid arthritis.145
e. Renal
In the field of nephrology, women seem to be better protected from developing end-stage
renal disease (ESRD) than men.146 In a community-based screening, it was found that ESRD
remained low during the reproductive years and began to rise ten years later in women than in
men.147 Further, the average age when dialysis treatment is started was found to be higher in
women than in men.148 As kidney function deteriorates with age, the extent of age-related
glomerular filtration rate (GFR) varies between the sexes.149 Additionally, a recent study with
more than 200,000 patients receiving dialysis showed that men were more likely than women to
be on dialysis if they had advanced kidney disease (fifty-nine percent men and forty-one percent
women).150

This observation does not shed light on underlying reasons or motivation for

continuing or stopping treatment; however, it illustrates disparities in treatment. Many of the
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questions about the sexes and their proportion of ESRD diagnoses remain unanswered; therefore,
it is imperative to conduct further research on this topic.
f. Hepatic
Women are more susceptible than men to developing acute liver failure, benign liver
lesions, primary biliary cirrhosis, and toxin-mediated hepatotoxicity.151 Potential reasons for this
increased susceptibility may include the effect of sex hormones on oxidative and metabolic
pathways, differential gene transcriptions in response to injury in women compared with men, and
sex-based differences in immune regulation.152 Women are more vulnerable than men to the
negative effects of alcohol and drug use on the liver. This fact is bolstered by a Denmark study of
13,000 participants that showed the risk of development of alcohol-related liver disease increased
in women who consumed between seven to thirteen beverages per week compared to men who
consumed fourteen to twenty-seven beverages per week.153 Even following the abstinence of
alcohol, women with alcoholic liver disease have a more rapid progression to fibrosis.154 Several
factors may contribute to the severity of alcoholic liver disease in women, which include: (1) a
higher endotoxin level; (2) increased gut permeability to endotoxins; (3) estrogen receptor
concentrations within the liver; and (4) the potential activation of liver Kupffer cells by estrogen,
leading to increased inflammation and necrosis.155
D. Sexual Orientation Reasoning Examples
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It has been well established by various research projects that health disparities exist among
the LGBTQIA+ community as a growing minority group. These biases are primarily rooted in
bias, stigma, discrimination and other social determinants of health, rather than biological genetics
or gender identity. The issues for this population group exist not only within underrepresentation
in clinical trials, but also in day-to-day healthcare. These issues can be solved through expansive
healthcare system changes and education changes, beginning with simple data collection and
reaching as far as research project formation. The examples of issues for healthcare correlating to
the sexual-orientation of patients are plentiful within these areas.
On a more general scale, the lack of data collection regarding gender identity begins with
the daily practitioner. Few clinical practitioners ask about sexual orientation or gender identity
during general check-ups. In locations where they do ask, practitioners have noted patient
reluctance to reveal personal information regarding their sexual orientation. Conversely, the issue
of physician discomfort and ignorance on the importance of the information still pervades the
medical field.156 As an example, discomfort with sharing their sexual identity can keep members
of the LGBTQIA+ community from seeking preventative healthcare for HIV/AIDS, resulting in
higher incidence rates in these populations.157 This, of course, only supports negative stereotypes,
which furthers problems for the community. Until and unless action is taken to educate physicians
and patients on the importance of disclosing sexual identity information, this discomfort will
continue to create problems for healthcare development and patient treatment.
Aside from long-term social problems, failing to collect information on a patient’s sexual
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orientation can lead to immediate issues for them, such as prolonged delay of treatment or even
incorrect diagnosis. One case study shows a fifty-year-old woman who was hospitalized for a high
fever and severe chills.158 Doctors spent hours trying to determine the source of the issue, and
eventually discovered that it was an infection in the prostate gland. If the practitioners had been
in the practice of collecting information on patients’ sexual orientation, the woman could have
received a speedier diagnosis and easier treatment. Similar examples to this exist for transgender
men as well.
Many are already working to solve these problems, which (as seen in the examples) stem
from social stigmas and other social issues, rather than biological problems themselves. One such
proposed solution is the invention of Patient Portals, an electronic way for patients to discreetly
and confidentially enter their personal information from home rather than using verbal answers to
awkward or embarrassing questions. The information becomes part of the patient’s medical
record.159 While solutions like this may aid the problem, the solution lies within education.
Educating receptionists and physicians at medical centers and throughout clinical trials about the
importance of such questions can help to provide more effective care for all people, regardless of
their specified sexual-orientation.160
E. The Cost of Exclusion
As the reasoning for collecting data on sexual orientation grows, funding agencies have
become more restrictive of their donations towards clinical trials. For example, as mentioned in
previous sections, the NIH has made the inclusion of a diverse group of sex and gender a
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requirement for funding in many cases, and other federal health research funding organizations
provide extra subsidies for demonstrated effort to include a wide range of sexual orientations and
genders in research.161 While such organizations explain that the exclusion of minority groups due
to excessive cost is not acceptable, concerns about finances for projects are still an issue.
Recruiting sufficient numbers of participants is difficult enough without considering a balanced
sex or gender ratio, and oftentimes the inclusion of minorities results in additional costs.162 For
example, the Society for Women’s Health Research guidelines have advised that research for sex
differences should use women in different hormonal states,163 which was shown to quadruple the
medical research grant costs. While these higher costs upfront can discourage researchers from
including a more diverse grouping of gender and sexual orientations (as well as other minorities),
excluding subpopulations can lead to the misapplication of new treatment plans.164 In the long
run, this will cost even more. However, it should be noted that there is little data on this subject,
since the mandated inclusion of a diverse range of sexes and genders is a relatively new concept.
E. Moving Forward
Although heart disease is sometimes thought of as a “man’s disease,” about the same
number of women and men die each year of heart disease in the United States. Despite increases
in awareness over the past decade, only fifty-four percent of women recognize that heart disease
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is also a woman’s number one killer.165 While chest pain is the most common symptom of a
heart attack, women can have symptoms that are not related to chest pain. Some of these subtle
symptoms include unusual fatigue: sweating; shortness of breath; and neck, jaw, or back pain.166
These subtle symptoms often make it more difficult for women to recognize that they are
experiencing a heart attack, and therefore, women are less likely than men to go to the
emergency room after a heart attack. There needs to be more awareness of the differences
between women and men relating to the presentation of angina pectoris and ACS. Studies and
guidelines should also consider sex-related differences when studying heart disease symptoms.
Healthcare professionals and researchers must include women in studies so that they can better
understand the biological differences between men and women that affect how they should be
treated.
Research on sex and gender differences in clinical and basic science research must
increase in the United States. Despite progress, many science researchers do not explore the
impact of sex on disease. Many studies simply do not include women or enough women to
analyze sex-based differences.167 The lack of inclusion of both sexes and analyses of the data
based on potential sex differences in all clinical and basic science research has far reaching
implications. The economic costs of not diagnosing, treating or administering the appropriate
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drugs and treatment, will continue to negatively impact utilization costs, development of
effective and appropriate treatment plans and limit specific and targeted drug discovery and
research initiatives.
G. AMWA Chicago Accelerator
As established by the previous sections, serious changes must be made to the systems of
healthcare innovation in order to support a broader spectrum of individuals. While these changes
must ultimately be made on a larger scale, independent accelerators have the potential to change
the way minorities are included in clinical trials. More importantly, they have the potential to
begin a revolution that will ultimately result in safer, better, and pioneering solutions in
healthcare for all people.
In general, an accelerator is meant to supply new innovation and grow companies with
support. In the healthcare industry, this means providing the resources necessary to succeed and
eventually spur innovation. These accelerators exist around the country and focus on various
sectors of healthcare.168 For example, Dreamit Health based in New York and Philadelphia aims
to help founders of companies find customers, perfect their marketing strategies, and raise
funding. They offer programs to initiate new companies, and ultimately help them with the
technology and development side of their ideas.169 Another example is MATTER based in
Chicago, which serves as an incubator for healthcare innovators. They help healthcare start-ups
by providing a healthcare and technology experts, access to important connections, and as a
whole, to accelerate the development of revolutionary healthcare technologies.170 Some
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accelerators work to specifically support minority groupings, such as women. Accelerators like
Avindé in Austin171 or The Brandery in Cincinnati support female founders for companies
through connection-based or financial methods.172
Few accelerators, however, focus on helping companies that seek to solve the sex and
gender bias in healthcare development. As this article has discussed, the inclusion of sex and
gender into clinical trial is incredibly important for developing beneficial healthcare for all
people. This is the goal of AMWAxcel, (AMWAxcel.com), an accelerator spearheaded by Dima
Elissa, MBA and Dr. Neelum Aggarwal under the American Medical Women’s Association
Diversity, Inclusion and Innovation Sector focusing on creating an environment for diversity and
inclusion in the spectrum of innovation.173 Groups like this are essential to overcome both
historical and existing biases in medical development. Through teamwork and collaboration of
Women-in-STEM accelerators across the globe, these biases can be replaced with a new era of
inclusive healthcare.
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